The effect of 12-month growth hormone treatment on obstructive sleep apnoea in abdominally obese men Source: Annual Congress 2008 - Alternatives for continuous positive airway pressure therapy in obstructive sleep apnoea Year: 2008
The effect of growth hormone therapy, adenotonsillectomy and genotype on obstructive sleep apnea in children with Prader-Willi syndrome Source: Annual Congress 2013 –Assessing sleep disordered breathing and lung function in children Year: 2013
Role of growth hormone-releasing hormone in sleep and growth impairments induced by upper airway obstruction in rats Source: Eur Respir J 2011; 38: 870-877 Year: 2011
Analysis of sleep cyclic alternating pattern (CAP) in children with Prader-Willi syndrome and effect of growth hormone treatment Source: Annual Congress 2008 - Sleep apnoea in childhood Year: 2008
Respiration and sleep in young individuals with Prader-Willi syndrome treated with growth hormone Source: Annual Congress 2005 - What should we know about our SAS patients Year: 2005
Effect of growth hormone (GH) therapy on obstructive sleep apnea (OSA) in children with Prader Willi Syndrome (PWS) Source: Eur Respir J 2005; 26: Suppl. 49, 614s Year: 2005
Sleep disturbances, daytime functioning and quality of life in patients with lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 782s Year: 2006
Sleep disordered breathing in Prader Willi syndrome post recombinant human growth hormone therapy Source: Annual Congress 2011 - Obstructive sleep apnoea as a comorbidity Year: 2011
Correlation between sleep parameters, physical activity and quality of life in somnolent moderate to severe obstructive sleep apnea adult patients Source: Annual Congress 2013 –Have we advanced in the treatment of sleep disordered breathing? Year: 2013
Anabolic effects and safety assessments of TH9507, a growth hormone releasing factor (GRF) analog, in patients with COPD-associated wasting Source: Eur Respir J 2004; 24: Suppl. 48, 292s Year: 2004
Growth hormone (GH) response to GH-releasing hormone (GHRH) in asthmatic patients during long-term inhaled corticosteroids (ICS) treatment Source: Eur Respir J 2003; 22: Suppl. 45, 419s Year: 2003
Cognition, quality of life and adherence to CPAP after 18-months treatment in obstructive sleep apnea patients Source: Annual Congress 2011 - Cardiometabolic and neurocognitive changes in obstructive sleep apnoea Year: 2011
Short term effects of neck-based treatment and monitoring device for positional obstructive sleep apnea Source: International Congress 2015 – To treat or not to treat? Sleep-disordered breathing II Year: 2015
Impact of sleep quality and comorbidities on health-related quality of life in patients with obstructive sleep apnea Source: International Congress 2019 – Consequences of sleep-disordered breathing from molecular and clinical points of view Year: 2019
Endocrinological disturbances in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: 76S-80S Year: 2003
Effects of TH9507, a growth hormone releasing factor (GRF) analog, on functional performance in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 245s Year: 2004
Evaluation quality of life, anxiety, and depression in patients with obstructive sleep syndrome before and after three and twelve months of continuous positive airway pressure therapy Source: Virtual Congress 2021 – Advances in therapeutic plans for sleep disordered breathing Year: 2021
Central and obstructive apnoea-hypopnea indices pre and post growth hormone commencement in children with Prader-Willi syndrome following introduction of a screening programme Source: Virtual Congress 2020 – Respiratory physiology and sleep: what is new? Year: 2020
Effect of nCPAP on quality of life (QoL) in professionally active patients with obstructive sleep apnea (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 113s Year: 2005
One year vitamin D and parathyroid hormone influence in patients with OSAS and CPAP treatment Source: International Congress 2018 – Treatments that can serve as an alternative to positive airway pressure (PAP) Year: 2018